Related Experiment Video

Updated: Apr 23, 2026

Three-dimensional Inflammatory Human Tissue Equivalents of Gingiva
08:43

Three-dimensional Inflammatory Human Tissue Equivalents of Gingiva

Published on: April 3, 2018

9.4K

Phenytoin effects on inflammatory mediator's production by gingival fibroblasts: a comparative study in children and

B Nazemisalman, S Vahabi1, M Bandehpour

  • 1Periodontics Unit, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Tel: 0098 2122403080;

Oral Health and Dental Management
|October 7, 2014
PubMed
Abstract

More Related Videos

Organotypic Tissue Model Systems for Investigating Host-Pathogen Interactions In Vitro08:41

Organotypic Tissue Model Systems for Investigating Host-Pathogen Interactions In Vitro

Published on: March 28, 2025

2.3K
Isolation, Characterization and Functional Examination of the Gingival Immune Cell Network05:07

Isolation, Characterization and Functional Examination of the Gingival Immune Cell Network

Published on: February 16, 2016

10.5K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
155
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
394
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
542